Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection

Expert Opinion on Biological Therapy

Volumn 15, Issue 5, 2015, Pages 641-650

  Caso, Francesco ^a   Cantarini, Luca ^b   Morisco, Filomena ^c   Del Puente, Antonio ^c   Ramonda, Roberta ^a   Fiocco, Ugo ^a   Lubrano, Ennio ^d   Peluso, Rosario ^c   Caso, Paolo ^e   Galeazzi, Mauro ^b   Punzi, Leonardo ^a   Scarpa, Raffaele ^c   Costa, Luisa ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF MOLISE   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adalimumab; Etanercept; Hepatitis C virus infection; Psoriatic arthritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL LITERATURE; MIXED INFECTION; PSORIATIC ARTHRITIS; REVIEW; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; DISEASE MANAGEMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HEPATITIS C VIRUS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DISEASE MANAGEMENT; HEPATITIS C; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927646270     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1011616     Document Type: Review

References (75)

1. Ansaldi F, Orsi A, Sticchi L, et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20: 9633-52
2. Penin F, Dubuisson J. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19
3. Gower E, Estes CC, Hindman S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61(1 Suppl): S45-57
4. Reddy KR, Bruno S, Rossaro L, et al. Predictors of sustained virologic response among treatment-nai've patients with hepatitis C virus genotype 1 when treated with boceprevir (boc) plus peginterferon alfa-2b/ribavirin (pr). J Hepatol 2011; 54: S190
5. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16
6. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: ameta-Analysis. J Hepatol 2009; 50: 1142-54
7. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C an update. Hepatology 2009; 49: 1335-74
8. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C a systematic review. JAMA 2014; 312: 631-40
9. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection aliment Pharmacol Ther 2014; 39: 478-87
10. Lormeau C, Falgarone G, Roulot D, et al. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 2006; 73: 633-8
11. Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep 2006; 8: 53-9
12. Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment autoimmun Rev 2008; 8(1): 1-4
13. Landau DA, Saadoun D, Calabrese LH, et al. The pathophysiology of HCV induced B-cell clonal disorders autoimmun Rev 2007; 6: 581-7
14. Monti G, Saccardo F, Castelnovo L, et al. Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a populationbased survey: the Origgio study autoimmun Rev 2014; 13: 609-14
15. Burrows NP, Norris PG, Alexander G, et al. Chronic hepatitis C infection and psoriasis. Dermatology 1995; 190: 173
16. Chouela E, Abeldano A, Panetta J, et al. Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. Int J Dermatol 1996; 35: 797-9
17. Taglione E, Vatteroni ML, Martini P, et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999; 26: 370-2
18. Palazzi C, D'Angelo S, Olivieri I. Hepatitis C virus-related arthritis autoimmun Rev 2008; 8: 48-51
19. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78
20. Soscia E, Sirignano C, Catalano O, et al. New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl 2012; 89: 49-53
21. Eder L, Law T, Chandran V, et al association between environmental factors and onset of psoriatic arthritis in patients with psoriasis arthritis Care Res (Hoboken) 2011; 63: 1091-7
22. Tillett W, Costa L, Jadon D, et al. The classification for psoriatic arthritis (CASPAR) criteria-A retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012; 39: 154-6
23. Marchesoni A, Atzeni F, Spadaro A, et al. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 2012; 39: 849-55
24. Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl 2012; 89: 4-6
25. Del Puente A, Esposito A, Parisi A, et al. Osteoporosis and psoriatic arthritis. J Rheumatol Suppl 2012; 89: 36-8
26. Costa L, Caso F, D'Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012; 31: 711-15
27. Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2010; 8: 331-4
28. Shang Q, Tam LS, Sanderson JE, et al. Increase in ventricular-Arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 2012; 51: 2215-23
29. Scarpa R, Manguso F, D'Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000; 27: 1241-6
30. Eder L, Jayakar J, Pollock R, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity ann Rheum Dis 2013; 72: 1956-61
31. Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford) 2015; 54(1): 20-8
32. Lubrano E, Scarpa R. Psoriatic arthritis: treatment strategies using antiinflammatory drugs and classical DMARDs. Reumatismo 2012; 64: 107-12
33. Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis ann Rheum Dis 2003; 62: 482-6
34. Galeazzi M, Bellisai F, Giannitti C, et al. Safety of cyclosporine in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection ann N Y Acad Sci 2007; 1110: 544-9
35. Galeazzi M, Giannitti C, Manganelli S, et al. Treatment of rheumatic diseases in patients with HCV and HIV infection autoimmun Rev 2008; 8: 100-3
36. Galeazzi M, Bellisai F, Manganelli S, et al. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients autoimmun Rev 2006; 5: 493-8
37. Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-41
38. Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCd molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 2014; 58: 61-9
39. Suryaprasad AG, Prindiville T. The biology of TNF blockade autoimmun Rev 2003; 2: 346-57
40. Scarpa R, Costa L, Atteno M, et al. Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother 2013; 14: 2311-13
41. Fiocco U, Sfriso P, Oliviero F, et al. Blockade of intra-Articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 2013; 80: 165-70
42. Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014; 33: 833-9.63
43. Scarpa R, Atteno M, Lubrano E, et al. The effectiveness and safety of TNFalpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 2011; 30: 1063-7
44. Atteno M, Costa L, Matarese A, et al. The use of TNF-A blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 2014; 33: 543-7
45. Fabbroni M, Cantarini L, Caso F, et al. Drug retention rates and treatment discontinuation among anti-TNF-A agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm 2014; 2014: 862969
46. Ash Z, Gaujoux-Viala C, Gossec L, et al a systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and metaanalysis informing the EULAR recommendations for the management of psoriatic arthritis ann Rheum Dis 2012; 71: 319-26
47. Fuchs I, Abu-Shakra M, Sikuler E. Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations. Isr Med Assoc J 2013; 15: 303-7
48. Vigano M, Degasperi E, Aghemo A, et al anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012; 12: 193-207
49. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2): 1-70
50. Park J, Kang W, Ryu SW, et al. Hepatitis C virus infection enhances TNFa-induced cell death via suppression of NF-kB. Hepatology 2012; 56: 831-40
51. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74
52. Freeman AJ, Marinos G, Ffrench RA, et al. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001; 79: 515-36
53. Larrea E, Garcia N, Qian C, et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-17
54. Torrado E, Cooper AM. Cytokines in the balance of protection and pathology during mycobacterial infections adv Exp Med Biol 2013; 783: 121-40
55. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010; 6: 165-74
56. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003; 14: 229-32
57. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 580-4
58. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006; 54: 361-2
59. De Simone C, Paradisi A, Capizzi R, et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006; 54: 1102-4
60. Pitarch G, Sanchez-Carazo JL, Mahiques L, et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007; 32: 18-22
61. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007; 26: 261-4
62. Linardaki G, Katsarou O, Ioannidou P, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007; 34: 1353-5
63. Cavazzana I, Ceribelli A, Cattaneo R, et al. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases autoimmun Rev 2008; 8: 104-6
64. Collazo MH, Gonza'lez JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P R Health Sci J 2008; 27: 346-7
65. Paradisi A, Caldarola G, Capizzi R, et al. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol 2010; 62: 1067-9
66. Garavaglia MC, Altomare G. Etanercept therapy in patients with psoriasis and concomitant HCV infection. Int J Immunopathol Pharmacol 2010; 23: 965-9
67. Cuchacovich R, Hagan J, Khan T, et al. Tumor necrosis factor-Alpha (TNF-A)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol 2011; 30: 133-7
68. Zanni M, Missale G, Santilli D, et al. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. Eur J Dermatol 2011; 21: 564-7
69. Mederacke I, Witte T, Wedemeyer H, et al. Successful clearance of hepatitis C virus with pegylated interferon a-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis ann Rheum Dis 2011; 70: 1343-4
70. Abuchar A, Vitiello M, Kerdel FA. Psoriasis treated with ustekinumab in a patient with hepatitis C. Int J Dermatol 2013; 52: 381-2
71. Colombo D, Chimenti S, Grossi P, et al. Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis-synergy study: a longitudinal observational study. Biomed Res Int 2014; 2014: 941767
72. Costa L, Caso F, Atteno M, et al. Long-term safety of anti-TNF-A in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014; 33: 273-6
73. Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-22
74. Cooper C, Shafran S, Greenbloom S, et al. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factoralpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy. Can J Gastroenterol Hepatol 2014; 28: 35-40
75. Afshar M, Martinez AD, Gallo RL, et al. Induction and exacerbation of psoriasis with Interferon-Alpha therapy for hepatitis C a review and analysis of 36 cases. J Eur Acad Dermatol Venereol 2013; 27: 771-8